98%
921
2 minutes
20
Anaplasia may be identified in a subset of tumors with a presumed pilocytic astrocytoma (PA) component or piloid features, which may be associated with aggressive behavior, but the biologic basis of this change remains unclear. Fifty-seven resections from 36 patients (23 M, 13 F, mean age 32 years, range 3-75) were included. A clinical diagnosis of NF1 was present in 8 (22%). Alternative lengthening of telomeres (ALT) was assessed by telomere-specific FISH and/or CISH. A combination of immunohistochemistry, DNA sequencing and FISH were used to study BRAF, ATRX, CDKN2A/p16, mutant IDH1 p.R132H and H3-K27M proteins. ALT was present in 25 (69%) cases and ATRX loss in 20 (57%), mostly in the expected association of ALT+/ATRX- (20/24, 83%) or ALT-/ATRX+ (11/11, 100%). BRAF duplication was present in 8 (of 26) (31%). H3-K27M was present in 5 of 32 (16%) cases, all with concurrent ATRX loss and ALT. ALT was also present in 9 (of 11) cases in the benign PA precursor, 7 of which also had ATRX loss in both the precursor and the anaplastic tumor. In a single pediatric case, ALT and ATRX loss developed in the anaplastic component only, and in another adult case, ALT was present in the PA-A component only, but ATRX was not tested. Features associated with worse prognosis included subtotal resection, adult vs. pediatric, presence of a PA precursor preceding a diagnosis of anaplasia, necrosis, presence of ALT and ATRX expression loss. ALT and ATRX loss, as well as alterations involving the MAPK pathway, are frequent in PA with anaplasia at the time of development of anaplasia or in their precursors. Additionally, a small subset of PA with anaplasia have H3-K27M mutations. These findings further support the concept that PA with anaplasia is a neoplasm with heterogeneous genetic features and alterations typical of both PA and diffuse gliomas.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314894 | PMC |
http://dx.doi.org/10.1111/bpa.12646 | DOI Listing |
IEEE Trans Comput Biol Bioinform
July 2025
Brain cancer has a very high mortality rate. Gliomas are the most common malignant brain tumors, causing this severe fatality. Recent biological investigations revealed that a holistic study of biomarkers, responsible for causing genetic mutations in gliomas, can ensure a comprehensive prognosis and treatment plan for the patients.
View Article and Find Full Text PDFCureus
July 2025
Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, JPN.
Objective L-methyl-C-methionine (MET)- and F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) are used to detect gliomas. However, the efficacy of MET-PET and FDG-PET in detecting gene alterations in gliomas remains unclear. Therefore, in this study, we evaluated the relationship between genetic alterations and PET tracer uptake in diffuse astrocytic glioma.
View Article and Find Full Text PDFBackground: A key to understanding cancer is to determine the impact on the cellular pathways caused by the repertoire of DNA changes accrued in a cancer cell. Exploring the interactions between genomic aberrations and the expressed transcriptome can not only improve our understanding of the disease but also identify potential therapeutic approaches.
Results: Using random forest models, we successfully identified transcriptional patterns associated with the loss of wild-type activity in cancer-related genes across various tumour types.
Int J Mol Sci
July 2025
Department of Science, Roma Tre University, Viale G. Marconi 446, 00146 Rome, Italy.
During carcinogenesis, cells must acquire a telomere maintenance mechanism in order to avoid telomere shortening-induced replicative senescence. While most tumors activate telomerase, a minority of them employ a recombinational mechanism called Alternative Lengthening of Telomeres (ALT). One of the most investigated features is the association between ALT and mutations, since this has been shown to be the gene with the highest rate of mutations among ALT tumors.
View Article and Find Full Text PDFClin Epigenetics
July 2025
Department of Medical Biochemistry and Cell Biology, Sahlgrenska Center for Cancer Research, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Neuroblastoma is a heterogeneous disease where patient stratification is critical for prognosis and treatment decisions and where it recently has been suggested that the presence of telomere maintenance mechanisms (TMM) should be considered in risk stratification. We investigated the utility of DNA methylation-based classification for neuroblastoma diagnostics by analysing 303 tumours samples from two cohorts. We show that of the total number of cases, an average of 90% of the samples classified as neuroblastoma, while 66% also achieved confident classification into the three NB subclasses: "MYCN-type", "ALT/TERT TMM positive" and "TMM negative".
View Article and Find Full Text PDF